<?xml version='1.0' encoding='utf-8'?>
<document id="22318159"><sentence text="3,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors."><entity charOffset="0-24" id="DDI-PubMed.22318159.s1.e0" text="3,5-Disubstituted indole" /><entity charOffset="65-77" id="DDI-PubMed.22318159.s1.e1" text="nitric oxide" /><pair ddi="false" e1="DDI-PubMed.22318159.s1.e0" e2="DDI-PubMed.22318159.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22318159.s1.e0" e2="DDI-PubMed.22318159.s1.e1" /></sentence><sentence text="A series of 3,5-disubstituted indole derivatives was designed, synthesized and evaluated as inhibitors of human nitric oxide synthase (NOS)"><entity charOffset="12-36" id="DDI-PubMed.22318159.s2.e0" text="3,5-disubstituted indole" /><entity charOffset="112-124" id="DDI-PubMed.22318159.s2.e1" text="nitric oxide" /><pair ddi="false" e1="DDI-PubMed.22318159.s2.e0" e2="DDI-PubMed.22318159.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22318159.s2.e0" e2="DDI-PubMed.22318159.s2.e1" /></sentence><sentence text=" Various guanidine isosteric groups were explored at the 5-position of the indole ring, while keeping the basic amine side chain such as N-methylpiperidine ring, fixed at the 3-position of the indole ring"><entity charOffset="9-18" id="DDI-PubMed.22318159.s3.e0" text="guanidine" /><entity charOffset="75-81" id="DDI-PubMed.22318159.s3.e1" text="indole" /><entity charOffset="112-117" id="DDI-PubMed.22318159.s3.e2" text="amine" /><entity charOffset="137-155" id="DDI-PubMed.22318159.s3.e3" text="N-methylpiperidine" /><entity charOffset="193-199" id="DDI-PubMed.22318159.s3.e4" text="indole" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e0" e2="DDI-PubMed.22318159.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e0" e2="DDI-PubMed.22318159.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e0" e2="DDI-PubMed.22318159.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e0" e2="DDI-PubMed.22318159.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e0" e2="DDI-PubMed.22318159.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e1" e2="DDI-PubMed.22318159.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e1" e2="DDI-PubMed.22318159.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e1" e2="DDI-PubMed.22318159.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e1" e2="DDI-PubMed.22318159.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e2" e2="DDI-PubMed.22318159.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e2" e2="DDI-PubMed.22318159.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e2" e2="DDI-PubMed.22318159.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e3" e2="DDI-PubMed.22318159.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22318159.s3.e3" e2="DDI-PubMed.22318159.s3.e4" /></sentence><sentence text=" Compounds having 2-thiophene amidine and 2-furanyl amidine groups (7, 8, 10 and 12) showed increased activity for human neuronal NOS and good selectivity over endothelial and inducible NOS isoforms"><entity charOffset="18-37" id="DDI-PubMed.22318159.s4.e0" text="2-thiophene amidine" /><entity charOffset="42-59" id="DDI-PubMed.22318159.s4.e1" text="2-furanyl amidine" /><pair ddi="false" e1="DDI-PubMed.22318159.s4.e0" e2="DDI-PubMed.22318159.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22318159.s4.e0" e2="DDI-PubMed.22318159.s4.e1" /></sentence><sentence text=" Compound 8 was shown to reverse (10mg/kg, ip) thermal hyperalgesia in the L(5)/L(6) spinal nerve ligation (neuropathic pain) model and was devoid of any significant drug-drug interaction potential due to cytochrome P450 inhibition or cardiovascular liabilities associated with the inhibition of endothelial NOS" /><sentence text="" /></document>